Coverage
-
April 28, 2026
A California federal jury on Tuesday cleared Armistice Capital and two of its executives on class action claims it pumped and dumped $250 million in Vaxart stock during the COVID-19 pandemic and violated federal securities law with insider trading.
16 other articles on this case.
View all »